Prophylactic Cancer Vaccine
EMSL Project ID
29795
Abstract
Are there a collection of neo-antigens produced by tumor cells at critical stages of a tumor growth such that if one were vaccinated against them most if not all tumors would be eliminated before they start? We propose that a concerted effort could determine if the prophylactic cancer vaccine concept was valid and produce the preclinical data to support a Phase I trial in less than 3 years. As the resource owner, we will analyze samples prepared from matched tumors and normal lymphocytes from the same patients to identify cancer-specific neo-peptides, using state-of-the-art liquid phase chromatography separation coupled to mass spectrometry (LC-MS) capabilities at PNNL. To achieve highly sensitive proteomics analysis, online solid-phase extraction (SPE)-nanoLC separations coupled to hybrid high mass resolution mass spectrometers will be used. A 120 m-i.d. capillary SPE C18 column will be connected online with a 30 m-i.d. capillary C18 analytical column for the analysis. The online SPE column allowed the direct analysis of high-salt (e.g., PBS) samples prepared using current protocol; the nanoLC-LTQ Orbitrap platform provides highly efficient separation and highly sensitive and accurate MS and MS/MS measurements. Only sub-micrograms of peptides are needed for each analysis. All raw MS/MS datasets will be examined manually and also searched against the custom frameshift database to identify the target peptides.
Project Details
Start Date
2008-08-07
End Date
2011-08-14
Status
Closed
Released Data Link
Team
Principal Investigator